INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal disorder of a pluripotent hemopoietic stem cell that harbours the BCR/ABL rearrangement, a molecular abnormality that results in the activation of an oncogenic protein, the Bcr/Abl tyrosine kinase, which confers the neoplastic cells a proliferative advantage over the benign hemopoietic progenitors (1) . Imatinib, a selective inhibitor of the Bcr/Abl protein, has changed dramatically the treatment of CML (2) . Following the publication of the early results of the IRIS trial (3), a phase 3 study that compared imatinib 400 mg daily versus interferon-alfa plus low-dose Ara-C in patients newly diagnosed with chronic-phase CML (CP-CML), imatinib became the frontline therapy for CML patients. Further updates of the IRIS trial have shown that the responses to imatinib are mostly durable and that treatment failures tend to occur at the beginning of therapy, with a steady decline being observed after two years (4, 5) . These results, which have been recently confirmed in an individual series (6) , were taken as a basis for the design of studies aimed at further improving the results of frontline imatinib therapy (7-10).
In the above context, the Spanish PETHEMA group undertook a collaborative study of early intervention during imatinib therapy in patients with de novo CP-CML.
The study was designed before publication of the first European LeukemiaNet recommendations for CML treatment (11) . Following the availability of the secondgeneration tyrosine kinase inhibitors (TKIs) dasatinib (12) and nilotinib (13), first in clinical trials and then in clinical practice, the study was amended to allow administration of these newer drugs in patients with failure or intolerance to imatinib, as well as imatinib dose increase in patients not in major molecular response at 18 months of © F e r r a t a S t o r t i F o u n d a t i o n treatment. The main goal of the present article is to report the results of the CML/PETHEMA study.
DESIGN AND METHODS

Patients and criteria of inclusion
Between July 2003 and August 2006, 215 patients consecutively diagnosed with
Ph-positive CP-CML in 47 institutions in Spain were registered for inclusion in the study, after approval by the local ethics committees. Criteria of inclusion were: age from 18 to 72 years, less than three months from diagnosis, performance status < 2 of the ECOG scale, negative HIV test, no pregnancy or breast feeding in fertile women, not having had a neoplasia for the preceding five years, renal and liver function tests lower than 1.5 times the upper normal range, and written informed consent in accordance with the Declaration of Helsinki. The reason to exclude patients over the age of 72 years was the possibility that they could be assigned to the interferon arm, considering the wellknown poor tolerability to this drug in the elderly. Five screening failures were registered, due to criteria of accelerated phase (two patients), and recent neoplasia, a positive pregnancy test and more than three months from diagnosis (one case each).
Therefore, 210 patients were finally included in the study. Their main characteristics are detailed in the Results section.
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Following the diagnosis of Philadelphia chromosome-positive CP-CML, the use of hydroxyurea was allowed for a maximum of 3 months. Imatinib was administered orally at a dose of 400 mg/day. At 3 months, in patients failing to achieve a complete hematologic response (CHR) the imatinib dose was increased to 800 mg daily, while it was maintained at 400 mg in the remaining patients. Then, depending on the cytogenetic response obtained at 6 months from imatinib start, patients were kept on imatinib 400 mg daily, if they had achieved a complete cytogenetic response (CCyR), or randomized to receive either higher imatinib doses (600 mg and then 800 mg) or imatinib 400 mg/day plus subcutaneous low dose interferon-alfa 2b (IFN, 3 million units 3 times a week) in case that a CCyR had not been attained at that time. The rationale to add IFN in one of the experimental arms was the fact that, before imatinib availability, it was the only drug able to produce consistent cytogenetic responses in CML. Since the International Scale (IS) had not been described at the time when the study was designed, a 3-log reduction in the BCR/ABL transcripts was initially employed to define a MMolR, following the example of the IRIS study (14) . However, once the IS was created (15) and the national standardization process carried out in Spain, the values at 18 months and thereafter were reassessed and expressed using the IS by means of a laboratory-specific conversion factor provided via the EUTOS for CML programme (http://www.eutos.org). Imatinib levels were not available during most of the study period and, therefore, they were not used for dose optimization purposes. Due to the availability of the second-generation CCyR, the BCR-ABL transcript levels were assessed in peripheral blood every 3 months by real-time quantitative polymerase chain reaction (RT-Q-PCR) according to standard methods, with GUS being used as control. As mentioned before, MMolR was initially defined as a 3-log reduction with regard to the baseline BCR/ABL transcript level (14) and later on expressed as a ratio BCR-ABL/control gene <0.1% of the IS (15) . Complete molecular response was defined as two consecutive samples with no detectable transcripts, corresponding to a >4.5 log-reduction in the BCR/ABL copies. The molecular studies were performed in three reference laboratories, located in Barcelona, Córdoba and Salamanca, Spain, which used the same technique and exchanged representative samples for cross-checking.
Criteria of response and loss of response
Complete hematologic response (CHR) was defined as normalization of the peripheral blood counts and leukocyte differential with disappearance of the palpable spleen. Cytogenetic response was graded according to standard criteria (11) . In case that 20 metaphases could not be obtained in the bone marrow study (which occurred in one or more occasions in a total of 29 patients), a CCyR was considered if less than 1% of the nuclei were positive for the BCR/ABL at FISH study of 200 or more cells from peripheral blood (16, 17) .
For the purpose of the present analysis, treatment failure was defined according to the updated criteria of the European LeukemiaNet (18) . In brief, it included the lack of CHR at 3 months of treatment, no cytogenetic response (bone marrow Ph+ cells > 95%) at 6 months, less than a partial cytogenetic response (i.e., Ph+ cells > 35%) at 12 months, lack of CCyR at 18 months, the loss of response anytime (defined as the loss of CHR, including also the progression to the accelerated or blastic phases, and the loss of CCyR), and death. The accelerated phase (AP) and blastic phase (BP) were defined according to standard criteria (11) . Overall survival was calculated as the time from imatinib start until death, whatever the cause. Progression-free survival (PFS) was defined as the time from imatinib start to the appearance of AP/BP or death, whatever the cause. Failure-free survival (FFS) was defined as the time from imatinib start to failure, including death, progression to AP/BP and the lack of achievement or the loss of a previously achieved CHR or CCyR. Event-free survival (EFS) included the above situations plus the permanent discontinuation of imatinib for any reason (e.g., intolerability, allogeneic stem cell transplantation, treatment of a second neoplasia or others).
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Statistical analysis
Survival and time to event curves were calculated from the start of imatinib by the method of Kaplan and Meier (19) Table 1 shows the main characteristics at diagnosis of the 210 patients. As can be seen, there was a predominance of patients in Sokal and Hasford low-risk groups and a low proportion of patients in the high-risk group (20, 21) . One hundred and forty-one could not be randomized because of toxicity (n= 3) or withdrawal of consent (n= 6) and were followed-up on an observational basis, 17 were assigned to higher imatinib dose, and 15 to imatinib 400 mg daily plus IFN. However, 6 of the latter patients withdrew consent and, therefore, only 9 patients actually started IFN, of whom one received the drug only for one month due to poor tolerability. Because of the scarce number of patients randomized, no comparison could be established between the two arms.
RESULTS
Of the 17 patients who underwent imatinib dose increase at 6 months, 16
achieved a CCyR at 18 months (without a MMolR in 4 cases), while the remaining one achieved the CCyR and also a MMolR at 24 months, while on high-dose imatinib. Two of the patients eventually lost the response: one of them, in whom the cause was lack of adherence to therapy, regained the response after resuming the high imatinib dose; the other one was derived to a second generation TKI and subsequently responded. Due to either poor tolerability to the 800 mg imatinib dose or persistence of the good response in the long term, imatinib dose was eventually reduced in most patients, to 600 (n=6) or 400 mg (n=8). All 17 patients were alive and in response at last follow-up.
Among the 15 patients assigned to the imatinib plus IFN arm, 7 of the 9 who actually started IFN were in CCyR at 18 months (with a MMolR in 6 cases) and 2 failed to achieve such a response. One of the latter 2 patients subsequently responded to higher imatinib dose, while the other one evolved into an AP that eventually responded to a second generation TKI. Of the 6 patients who withdrew consent to receive IFN, one was submitted to an allo-SCT shortly afterwards while in the chronic phase of CML, one © F e r r a t a S t o r t i F o u n d a t i o n patient evolved into AP and was also transplanted, other responded to imatinib dose escalation, and the remaining 3 continued on imatinib 400 mg daily. All patients were alive at last follow-up.
In the group of 156 patients in CCyR at 6 months, during the period from the 6 to the 18 months the following events were registered: evolution to AP/BP (2 cases, one of them successfully rescued with an allo-SCT), imatinib discontinuation due to toxicity (2 patients) or appearance of a second neoplasia (1 case), allo-SCT while in response to imatinib (1 case), loss to follow-up (2 patients), and loss of the cytogenetic response (6 cases). Of the remaining patients, 16 were not in MMolR at 18 months and 9 of them were dose escalated. In the remaining 7, the reasons for not increasing the imatinib dose were that the amendment recommending escalation in such situation was implemented in January 2006 (n= 6) and a death from an unrelated cause (n= 1). Of the 9 patients who were dose escalated at 18 months, 8 achieved a MMolR following escalation, while the remaining one developed cytogenetic resistance a few months later and was switched to a second-generation TKI. In the overall group of patients in CCyR at 6 months, 3
additional cases of AP/BP were registered after the initial 18 months of therapy.
Finally, among the 7 patients not assessable for cytogenetic response at 6 months, one developed sudden BP shortly afterwards and died. On turn, of the 9 patients not in CCyR at 6 months and not being randomized because of toxicity or withdrawal of consent, 6 were kept on imatinib at lower or higher dosages (depending on whether the reason for the lack of randomization was toxicity or withdrawal of consent) and 3 were switched to a second generation TKI. No instance of evolution to AP/BP has been registered in the latter group of patients.
In the overall group of patients, cumulative response rates at 3 years were: CHR 98.6%, CCyR 90%, and MMolR 82% (figure 2). On an ITT basis, CCyR rate was 78.8%
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at 18 months; at last follow-up, MMolR and complete molecular response rates were 63% and 38%, respectively. No association was found between any of the initial clinical and laboratory features evaluated and the lack of CCyR at 12 and 18 months on imatinib.
Moreover, no differences were noted in CCyR rate according to Sokal or Hasford risk groups, although it must be noted that the proportion of patients in the high-risk group was low.
With current follow-up, only 5 of the 210 patients have died, one of them from a CML-unrelated cause (poisoning) while in CCyR to standard-dose imatinib. Evolution into AP/BP was seen in 9 patients: 3 in the first year of treatment, 3 in the second year, 2
in the third year, and 1 in the fourth year, whereas no instance of such complication has been observed so far in patients having completed their fifth year of treatment. With regard to the characteristics of the 9 patients developing AP/BP, only 2 belonged to
Sokal's low-risk group, while the remaining 7 had intermediate (n= 5) or high-risk (n=2)
CML. Eight patients were lost to follow-up, 9 discontinued imatinib because of toxicity, 3 due to the appearance of a second neoplasia, and 2 female patients because of pregnancy. Five patients underwent allo-SCT between 13 and 27 months from diagnosis:
3 were in CP-CML at time of transplantation (2 in response to imatinib and 1 after losing a previously achieved CCyR) and 2 had evolved to AP/BP. At last follow-up, 131
patients were receiving an imatinib daily dose of 400 mg, 23 patients 600 mg, 7 patients 800 mg and 4 patients 300; 16 patients were on dasatinib and 6 on nilotinib. Figure 3 shows the curves of overall survival and PFS. As can be seen, at 5 years, overall survival was 97.5% and PFS 94.3%. Figure 4 depicts the actuarial curves of FFS and EFS, the 5-year projected percentages being 82.5% and 71.5%, respectively.
During imatinib treatment, a total of 27 patients (12.8% of the overall group) experienced grade 3-4 hematologic toxicity of the WHO scale, including neutropenia hematologic toxicity was observed during the first 6 months of therapy in 20 patients.
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After this time period, it was observed in 3 non-randomized patients, in 3 patients of the imatinib plus IFN arm and in one of those assigned to high-dose imatinib. In only 5
patients the hematologic toxicity appeared beyond one year of therapy. Seven patients required temporary administration of G-CSF for recurrent neutropenia. With regard to grade 3-4 non-hematologic side effects, they occurred in 32 patients (15.4% of the series), the most frequent one being liver toxicity (5.7%). These grade 3-4 nonhematologic side effects were registered in 13 patients during the first 6 months of therapy; after such a period they were observed in 17 of the non-randomized patients and in 1 of those receiving high-dose imatinib. Seventy of the 210 patients required transient imatinib interruption due to toxicity, in a total of 91 occasions (one episode, 42 patients; two episodes, 21 patients; three or more episodes, 7 patients). Median duration of the imatinib discontinuation periods was 1 week (range: 0.6-13). Three patients developed a second neoplasia (uterus, lung, and pancreas) while on imatinib treatment.
DISCUSSION
The introduction of imatinib has changed dramatically the outcome of CML patients. Following the favorable results of imatinib in patients resistant or intolerant to IFN (22) , the IRIS study showed that frontline imatinib therapy of CP-CML results in high rates of complete cytogenetic and major molecular responses in the short and mid term (3, 4) , that these responses are mostly durable in the long term (4, 5) , and that a progressive deepening in the molecular response is observed over time with continuous treatment (5). All of these achievements have translated into historically high rates of overall and progression-free survival in this disease (5) . The results of the IRIS study have been confirmed in the single center series of the Hammersmith hospital (6) .
Following the publication of the early results of the IRIS, collaborative efforts were initiated to further improve the results of imatinib therapy (7) (8) (9) (10) . However, to date, only the early results of two such studies have been published in regular form (7, 8) , whereas the preliminary results of other studies have been communicated in abstract form (9,10).
In the above context, the Spanish PETHEMA group undertook a collaborative study of early intervention during imatinib therapy in 210 patients newly diagnosed with CP-CML. Since the study was designed prior to the publication of the first recommendations of the European LeukemiaNet for the management of CML (11), the criteria triggering early intervention were different, but actually more stringent. Thus, the design was aimed at early intervention in case that a very good response had not been obtained in the early period of therapy. In addition, during the study progress, an increase in the imatinib dose was also recommended in case that a major molecular response had not been achieved at 18 months of treatment, a policy subsequently adopted by the
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European LeukemiaNet, which considered as suboptimal response the lack of MMolR by that time (11) . Additionally, advantage was also taken of the availability of the second generation TKIs dasatinib and nilotinib for patients who failed or were intolerant to imatinib (12, 13).
In explaining the improved results of the present study as compared with those of the IRIS, it must be noted that the two populations were not totally comparable, since our patients were younger and had a better risk profile than those in the IRIS. Part of the differences between the two series can be ascribed to the inferior upper age limit (72 years) established for inclusion in our study. However, this seems not to be the only reason for the differences. Indeed, it is well known that in Mediterranean countries median age at CML diagnosis and the proportion of high-risk patients are lower than in USA and other countries from Central and Northern Europe. Thus, in a CML series from Spain, including all patients consecutively diagnosed in a single institution over a long period of time, median age at diagnosis was 46 years (23). Moreover, the younger age and lower risk profile of the Italian as compared with the German patients was also pointed out (24). This having been said, it seems also logical to ascribe part of the better results obtained in the present study to the prompter institution of imatinib in our patients, who started the TKI at a median of only 2 weeks from diagnosis, with almost three quarters of them being already on imatinib within one month from diagnosis. This is in contrast with the IRIS study, in which median interval from diagnosis to imatinib start was 2.1 months and some of the patients started imatinib as late as 10.4 months from diagnosis (3). Two other facts would also likely contribute to our better results.
First, earlier intervention, as soon as at 3 and at 6 months, in case of inappropriate response, a maneuver not allowed in the IRIS, as it was a registration study. Secondly, greater experience in the management of the toxicity to imatinib, and especially of the © F e r r a t a S t o r t i F o u n d a t i o n cytopenias, allowing the early use of G-CSF to maintain dose intensity as much as possible, an intervention not permitted during the early phase of the IRIS study.
In the present study, a high rate of CHR was achieved at three months of imatinib therapy, with only four of the 210 patients failing to achieve such a response by that time.
Of note, two out of the four patients who were not in CHR at three months of treatment subsequently failed to imatinib dose increase, an observation that confirms the poor prognosis of the lack of CHR at three months previously reported by the Hammersmith group (25) and lends additional support to the consideration of this situation as a treatment failure in the updated recommendations of the European LeukemiaNet (18).
The higher than expected proportion of patients already in CCyR at 6 months in the present study (73.8% versus 52% in the IRIS) precluded comparison between the two randomization arms. It must also be noted that almost one quarter of the patients eligible for randomization at 6 months could not be randomized due to severe toxicity at the time of randomization or refusal of randomization once they faced the immediate possibility of receiving IFN. Actually, of the 15 patients assigned to the IFN arm, 6 withdrew consent once they were informed of the result of randomization, whereas an additional patient stopped IFN after one month because of poor tolerability. This refusal or low compliance of IFN should not be surprising, given the convenient administration form and usual good tolerability of imatinib, as opposed to the subcutaneous administration and frequent side effects of IFN. As a result, only 8 of the 210 patients of the study finally received low doses of IFN for one year, which means that, in practice, the study virtually consisted of imatinib optimization. On an ITT basis, the CCyR rate increased from 73.8% at 6 months to 78.8% at 18 months. Such modest increase is explained by the already good results at 6 months and also by the fact that, although a majority of patients randomized to higher imatinib dose or to imatinib plus IFN actually achieved a
CCyR at one year of randomization (i.e., at 18 months of imatinib start), this was partially counterbalanced by some CCyR losses, occasional evolution to AP/BP, allo-SCT (in some cases while in response to imatinib), imatinib discontinuation due to intolerance or appearance of a second neoplasia, and loss to follow-up. Cumulative rate of MMolR at 3 years was 82%. On an ITT basis, it was 63% at last follow up, with 38% of patients being in complete molecular response.
The fact that no prognostic factors for the achievement of CCyR could be identified in our patients might be attributed to the size of the series but, especially, to the high rate of favorable responses obtained.
Survival of patients in the present study was highly favorable, with an overall survival of 97.5% at 5 years and a survival free from evolution to AP/BP of 94.3%. In keeping with the results of the IRIS and Hammersmith studies (5, 6) , the unfavorable events tended to accumulate during the first years of treatment and progressively declined after the third year. This observation would reinforce the relevance of achieving an early favorable response to imatinib to prevent disease progression (26). In this sense, the latter notion has represented the basis for the use of more stringent criteria for the early assessment of response in the new recommendations by the European LeukemiaNet (18) , in order to identify as soon as possible those patients without an adequate response to imatinib, which should trigger early therapeutic interventions. On the other hand, EFS at 5 years was 71% in our patients. It must be noted that the term EFS has a different meaning in the present study and in the IRIS, in which it was formerly known as PFS (3, 4) and renamed as EFS in the last update report (5) . Thus, in our study, EFS encompassed primary/secondary resistance, evolution to AP/BP, death from any cause, and the definitive discontinuation of imatinib for any reason, using the concept coined by the Hammersmith group (6), as it represents a more realistic approach than considering © F e r r a t a S t o r t i F o u n d a t i o n the events of progression only. By contrast, in the IRIS study, EFS refers to death from any cause, evolution to AP/BP, and primary/secondary resistance, but it does not include the definitive discontinuation of imatinib for any reason. This would explain the apparent discrepancy between the two studies, but also the concordance of our results with those reported by the Hammersmith group (6).
In our patients, toxicity to imatinib was generally moderate. Thus, although grade 1 and 2 non-hematologic side effects were frequent during the early period of treatment (data not shown), grade 3-4 non-hematologic toxicity was relatively low and it occurred mostly at the beginning of therapy. With regard to hematologic side effects, a low rate of grade 3-4 hematologic toxicity was observed, mainly consisting of neutropenia, which usually appeared during the first year of treatment and could be managed with temporary imatinib discontinuation or dose reduction or with the addition of G-CSF in the few patients with recurrent episodes of such complication. This policy allowed adequate dose intensity and the continuous administration of the drug in the majority of patients, a fact likely contributing to the favorable therapeutic results obtained in the present study.
In conclusion, prompt institution of imatinib, early intervention in case of inadequate response and improved management of toxicity, together with rescue of resistant patients with second-generation TKIs, could improve the outcome of patients newly diagnosed with CP-CML. Ongoing studies comparing imatinib upfront with the second generation TKIs will allow to determine whether these outstanding results can be improved further. 
